Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients.
Antithrombin III
Danaparoid sodium
Liver cirrhosis
Portal vein thrombosis
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
16 Dec 2019
16 Dec 2019
Historique:
received:
22
01
2019
accepted:
09
12
2019
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
10
5
2020
Statut:
epublish
Résumé
Portal vein thrombosis (PVT) is a common complication of cirrhosis. However, in patients with PVT and cirrhosis, there is no clear evidence supporting effective treatment modalities. In this study, we examined the effectiveness and safety of anticoagulation therapy using danaparoid sodium for PVT in patients with cirrhosis. This retrospective study assessed 52 cirrhotic patients with PVT treated with danaparoid sodium for 2 weeks between November 2008 and September 2018. The primary outcome measure was the post-treatment status of PVT assessed by reduction in thrombus volume and safety of the therapeutic intervention. PVT status was evaluated with contrast-enhanced computed tomography (CECT). All patients received 1250 units of danaparoid sodium twice daily by intravenous injection for 14 days. Patients on antithrombin III (AT-III) combination therapy were additionally administered 1500 units of AT-III on days 1-5 and days 8-12. Effectiveness was evaluated by CECT from between days 13 and 18. The secondary outcome measure was the prognosis of PVT. All patients showed reduction in PVT volume without complications. Return of plasma AT-III level to > 70% during the treatment period contributes to ≥75% reduction of PVT volume. The prognosis in PVT patients depends on hepatic reserve capacity. When limited to Child-Pugh B and C liver cirrhosis patients, a ≥ 75% reduction of PVT volume improved the prognosis. Danaparoid sodium-based anticoagulation therapy was effective and safe for PVT in patients with cirrhosis. Return of plasma AT-III level to the normal range during the treatment period contributes to reduction of PVT volume. A reduction of ≥75% in PVT volume may improve the prognosis of Child-Pugh B and C decompensated cirrhosis patients with PVT.
Sections du résumé
BACKGROUND
BACKGROUND
Portal vein thrombosis (PVT) is a common complication of cirrhosis. However, in patients with PVT and cirrhosis, there is no clear evidence supporting effective treatment modalities. In this study, we examined the effectiveness and safety of anticoagulation therapy using danaparoid sodium for PVT in patients with cirrhosis.
METHODS
METHODS
This retrospective study assessed 52 cirrhotic patients with PVT treated with danaparoid sodium for 2 weeks between November 2008 and September 2018. The primary outcome measure was the post-treatment status of PVT assessed by reduction in thrombus volume and safety of the therapeutic intervention. PVT status was evaluated with contrast-enhanced computed tomography (CECT). All patients received 1250 units of danaparoid sodium twice daily by intravenous injection for 14 days. Patients on antithrombin III (AT-III) combination therapy were additionally administered 1500 units of AT-III on days 1-5 and days 8-12. Effectiveness was evaluated by CECT from between days 13 and 18. The secondary outcome measure was the prognosis of PVT.
RESULTS
RESULTS
All patients showed reduction in PVT volume without complications. Return of plasma AT-III level to > 70% during the treatment period contributes to ≥75% reduction of PVT volume. The prognosis in PVT patients depends on hepatic reserve capacity. When limited to Child-Pugh B and C liver cirrhosis patients, a ≥ 75% reduction of PVT volume improved the prognosis.
CONCLUSIONS
CONCLUSIONS
Danaparoid sodium-based anticoagulation therapy was effective and safe for PVT in patients with cirrhosis. Return of plasma AT-III level to the normal range during the treatment period contributes to reduction of PVT volume. A reduction of ≥75% in PVT volume may improve the prognosis of Child-Pugh B and C decompensated cirrhosis patients with PVT.
Identifiants
pubmed: 31842768
doi: 10.1186/s12876-019-1140-8
pii: 10.1186/s12876-019-1140-8
pmc: PMC6915942
doi:
Substances chimiques
Anticoagulants
0
Dermatan Sulfate
24967-94-0
Chondroitin Sulfates
9007-28-7
Heparitin Sulfate
9050-30-0
danaparoid
BI6GY4U9CW
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
217Références
Gut. 2005 May;54(5):691-7
pubmed: 15831918
Eur J Intern Med. 2015 Jan;26(1):23-9
pubmed: 25566699
J Clin Gastroenterol. 2010 Jul;44(6):448-51
pubmed: 19730112
BMC Med. 2018 Jun 5;16(1):83
pubmed: 29871683
N Engl J Med. 2010 Dec 23;363(26):2499-510
pubmed: 21128814
Liver Int. 2012 Jul;32(6):919-27
pubmed: 22435854
Hepatol Res. 2018 Feb;48(3):E107-E116
pubmed: 28666312
N Engl J Med. 2013 Feb 21;368(8):699-708
pubmed: 23216615
Clin Gastroenterol Hepatol. 2012 Jul;10(7):776-83
pubmed: 22289875
N Engl J Med. 2013 Oct 10;369(15):1406-15
pubmed: 23991658
BMC Gastroenterol. 2017 Oct 25;17(1):112
pubmed: 29070023
Hepatol Res. 2018 Jan;48(1):51-58
pubmed: 28342265
J Orthop Surg (Hong Kong). 2009 Apr;17(1):6-9
pubmed: 19398784
World J Gastroenterol. 2006 Apr 7;12(13):2115-9
pubmed: 16610067
World J Hepatol. 2015 Nov 28;7(27):2774-80
pubmed: 26644821
Dig Dis Sci. 2013 Jun;58(6):1776-80
pubmed: 23314858
J Am Coll Surg. 2000 Jul;191(1):76-92
pubmed: 10898187
Liver Transpl. 2006 Oct;12(10):1544-51
pubmed: 17004250
J Clin Exp Hepatol. 2015 Mar;5(1):22-40
pubmed: 25941431
J Hepatol. 2005 Jul;43(1):167-76
pubmed: 15925423
Dig Endosc. 2010 Jan;22(1):1-9
pubmed: 20078657
Hepatol Res. 2015 Jun;45(6):656-62
pubmed: 25088236
Scand J Gastroenterol. 2012 Jun;47(6):686-91
pubmed: 22472055
Hepatology. 2009 May;49(5):1729-64
pubmed: 19399912
Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):435-46
pubmed: 24686266
Hepatol Res. 2018 Mar;48(4):244-254
pubmed: 28902450
World J Hepatol. 2014 Feb 27;6(2):64-71
pubmed: 24575165
Gastroenterology. 2001 Feb;120(2):490-7
pubmed: 11159889
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354